Takeda Pharmaceutical Company Limited
TAK
|
News
|
$13.185
0.19%
430K
|
Health Technology
(0.0% 1d) (-9.6% 1m) (-21.0% 1y) (0.0% 2d) (0.0% 3d) (-0.2% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 41,728,120,715
http://www.takeda.co.jp
Sec Filling | Patents | 47495 employees
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
diagnostics qdenga dengue vaccine
add to watch list Paper trade email alert is off
Press-releases
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 02:00) - prnewswire.com
TAK | News | $13.185 0.19% 430K
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
MIRM | $23.7 0.55% 110K
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
report million reach treatment market
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.185 0.19% 430K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors
Published: 2024-04-15 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.185 0.19% 430K
|
Health Technology
|
| O: -1.19%
H: 0.26%
C: -0.98%
company
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.185 0.19% 430K
|
Health Technology
|
| O: 1.84%
H: 0.24%
C: -0.14%
adzynma japan takeda approval injection
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
TAK | News | $13.185 0.19% 430K
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.96%
CNTG | $0.461 14K
|
Commercial Services
|
| O: 1.43%
H: 1.41%
C: -1.41%
partnership genetic takeda disorders
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.185 0.19% 430K
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.96%
iclusig fda drug takeda approval application
Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.185 0.19% 430K
|
Health Technology
|
| O: 0.21%
H: 0.97%
C: 0.7%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 0.05%
H: 0.14%
C: -0.93%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.7%
H: 0.73%
C: -0.16%
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
REGN | $894.71 0.08% 180K
|
Health Technology
|
| O: -0.27%
H: 1.26%
C: 0.84%
AMGN | $266.895 1.58% 950K
|
Health Technology
|
| O: 0.2%
H: 1.14%
C: -1.18%
antibody therapeutics market
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.185 0.19% 430K
|
Health Technology
|
| O: 0.21%
H: 0.17%
C: 0.14%
tak-079 positive topline potential results study
Alexandria Real Estate Equities, Inc. Announces Significant Early Renewal and 10-Year Lease Extension With Longstanding Credit Tenant Takeda at the Alexandria Center at Kendall Square Mega Campus in Cambridge
Published: 2024-03-04 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.185 0.19% 430K
|
Health Technology
|
| O: -0.69%
H: 0.35%
C: 0.14%
ARE A | $117.65 0.98% 180K
|
Finance
|
| O: -0.01%
H: 1.98%
C: 1.41%
extension
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
TAK | News | $13.185 0.19% 430K
|
Health Technology
|
| O: 0.0%
H: 0.47%
C: 0.2%
vaccine dengue tak-003 qdenga
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 75% | 25% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Last 48 Hours Insiders Buying
CLSD | $1.42 7.58% 130K
|
Health Technology
|
14:00
CDZI P 25000 | $2.25 100K
|
Utilities
|
14:00
ETST P 39000 | $0.068 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.62 2.08% 8K
|
Finance
|
12:30
ADMQ | $0.0532 480K
|
|
10:30
AXR P 2400 | $21.02 -5.19% 3.5K
|
Finance
|
21:00
QCRH P 118 | $56.48 1.93% 15K
|
Finance
|
18:01
VUZI P 7500 | $1.26 230K
|
Electronic Technology
|
18:00
RMCF | $3.57 0.56% 7.9K
|
Consumer Non-Durables
|
20:10